Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Dispenzieri A, Coelho T, Conceição I, Waddington-Cruz M, Wixner J, Kristen A, Rapezzi C, Planté-Bordeneuve V, Gonzalez-Moreno J, Maurer M, Grogan M, Chapman D, Amass L September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

A consolidated overview of 14 years of global data from the Transthyretin Amyloidosis Outcomes Survey

View Presentation
Poster
Rozenbaum M, Tran D, Bhambri R, Nativi-Nicolau J September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

Annual cardiovascular-related hospitalization days avoided with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy

View Presentation
Poster
Hoffman JE, Gundapaneni B, Sultan MB, Elliott P September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

Five-year survival with tafamidis in patients with transthyretin amyloid cardiomyopathy

View Presentation
Poster
Munzu C, Glass O, Munteanu C, Sultan MB September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

Global Prevalence of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

View Presentation
Poster
Rozenbaum M, Tran D, Li B, Bhambri R, Postma M.J, Masri A September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

Modelling lifetime survival gain in patients with transthyretin amyloid cardiomyopathy and baseline NYHA class III: An analysis of ATTR-ACT and long term extension studies

View Presentation
Poster
Campbell C, LoRusso S, Dispenzieri A, Kristen A, Maurer M, Rapezzi C, Lairez O, Drachman B, Garcia-Pavia P, Grogan M, Chapman D, Amass L September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

Sex-related differences in cardiac involvement in wild-type transthyretin amyloidosis

View Presentation
Poster
Elliott P, Klein AL, Fernandes F, Gundapaneni B, Sultan MB, Shah SJ September 14, 2021 HFSA 2021 Transthyretin Amyloidosis (ATTR)

Tafamidis reduces the decline in longitudinal strain and stroke volume in patients with transthyretin amyloid cardiomyopathy

View Presentation